Skip to main content
SP5007,652.86-0.28%DOW53,417.16+0.26%NASDAQ25,980.19-0.76%BTC$79,623.00+2.76%ETH$2,494.81+1.53%GOLD$4,751.30+1.14%OIL$84.91-0.12%
Smart Investors Daily
Sign InSign Up Free
AL

NASDAQ · ALVR

AlloVir, Inc.

Healthcare · Biotechnology

$9.81

Up+$0.39 (+4.14%)

Updated Aug 25, 2026, 6:53 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
49.48M
P/E ratio
-3.78
Dividend yield
0.00%
52-week range
— – —
Volume
9.4K
Avg. volume
22.94K

Price performance

ALVR price history

1M range · 0 trading sessions · Daily adjusted prices

ALVR does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ALVR news

The latest Smart Investors Daily articles mentioning ALVR.

Stock researchCompany · Overview

ALVR research

Overview

Company profile and research snapshot.

Company profile

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ALVR recent ratings
DateFirmRatingTarget
Dec 26, 2023B of A SecuritiesUnderperform—
Dec 22, 2023Leerink PartnersMarket Perform—
Dec 22, 2023Piper SandlerNeutral—
Dec 22, 2023JP MorganUnderweight—
Aug 18, 2023B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Oct 31, 2025

Head to Head Review: AlloVir (NASDAQ:ALVR) versus SQZ Biotechnologies (NYSE:SQZ)

Valuation and Earnings This table compares SQZ Biotechnologies and AlloVir"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SQZ Biotechnologies $18.16 million 0.04 -$79.46 million ($2.61) -0.01 AlloVir N/A N/A -$190.42 million ($20.23) -0.24 SQZ Biotechnologies has higher revenue and earnings than AlloVir. AlloVir

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By